CAMBRIDGE, Mass. & MENLO PARK, Calif.--(BUSINESS WIRE)--Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based ...
NEW HAVEN, Conn.--(BUSINESS WIRE)--Verinomics, a leader in agricultural genomics and gene editing, today unveiled two breakthrough platforms designed to accelerate specialty crop innovation: Genesis™, ...
A pair of privately-held developers of editing-based therapies have some successes to show for their recent efforts to address the longtime challenge of bringing their treatments to patients by ...
Roche has added to its flotilla of RNA alliances, handing Ascidian Therapeutics $42 million upfront to use an alternative to gene editing to treat neurological diseases. The agreement includes up to ...
Cibus, Inc. announced significant advancements in its gene editing technology, particularly the establishment of production standards for its proprietary RTDS gene editing system, which enables the ...
LOS ANGELES, Nov. 11, 2025 /PRNewswire/ -- After years of confidential development — and fresh off an exclusive Deadline report on Nov. 10 — TACHI AI, a pioneering AI startup founded by filmmakers, ...
Collaboration combines Intellia’s leading CRISPR-based platform, including its DNA writing technology, with ReCode’s proprietary Selective Organ Targeting (SORT) lipid nanoparticle (LNP) to extend the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback